Rivaroxaban for secondary stroke prevention in patients with embolic strokes of undetermined source: Design of the NAVIGATE ESUS randomized trial

BACKGROUND: Embolic strokes of undetermined source comprise up to 20% of ischemic strokes. The stroke recurrence rate is substantial with aspirin, widely used for secondary prevention. The New Approach riVaroxaban Inhibition of Factor Xa in a Global trial versus ASA to prevenT Embolism in Embolic St...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Eur Stroke J
Hauptverfasser: Hart, Robert G, Sharma, Mukul, Mundl, Hardi, Shoamanesh, Ashkan, Kasner, Scott E, Berkowitz, Scott D, Pare, Guillaume, Kirsch, Bodo, Pogue, Janice, Pater, Calin, Peters, Gary, Davalos, Antoni, Lang, Wilfried, Wang, Yongjun, Wang, Yilong, Cunha, Luis, Eckstein, Jens, Tatlisumak, Turgut, Shamalov, Nikolay, Mikulik, Robert, Lavados, Pablo, Hankey, Graeme J, Czlonkowska, Anna, Toni, Danilo, Ameriso, Sebastian F, Gagliardi, Rubens J, Amarenco, Pierre, Bereczki, Daniel, Uchiyama, Shinichiro, Lindgren, Arne, Endres, Matthias, Brouns, Raf, Yoon, Byung-Woo, Ntaios, George, Veltkamp, Roland, Muir, Keith W, Ozturk, Serefnur, Arauz, Antonio, Bornstein, Natan, Bryer, Alan, O’Donnell, Martin J, Weitz, Jeffrey, Peacock, Frank, Themeles, Ellison, Connolly, Stuart J
Format: Artigo
Sprache:Inglês
Veröffentlicht: SAGE Publications 2016
Schlagworte:
Protocol
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6301240/
https://ncbi.nlm.nih.gov/pubmed/31008276
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2396987316663049
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge